Bcwm LLC Purchases New Position in Heartflow, Inc. $HTFL

Bcwm LLC purchased a new stake in shares of Heartflow, Inc. (NASDAQ:HTFL) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 31,139 shares of the company’s stock, valued at approximately $908,000.

A number of other institutional investors also recently modified their holdings of the business. Legal & General Group Plc bought a new position in shares of Heartflow in the 3rd quarter worth $59,000. Strs Ohio bought a new position in shares of Heartflow in the 4th quarter worth $99,000. Staley Capital Advisers Inc. bought a new position in shares of Heartflow in the 4th quarter worth $204,000. Legato Capital Management LLC bought a new position in shares of Heartflow in the 3rd quarter worth $243,000. Finally, Sandia Investment Management LP bought a new position in shares of Heartflow in the 3rd quarter worth $252,000.

Insider Buying and Selling at Heartflow

In other Heartflow news, insider Campbell Rogers sold 9,219 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the completion of the sale, the insider directly owned 78,731 shares in the company, valued at approximately $2,231,236.54. This trade represents a 10.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $29.12, for a total transaction of $657,005.44. Following the sale, the chief executive officer owned 519,397 shares of the company’s stock, valued at approximately $15,124,840.64. This represents a 4.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 2,205,971 shares of company stock worth $64,199,945. 7.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut their price objective on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. William Blair assumed coverage on shares of Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating for the company. Wells Fargo & Company upped their price objective on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Canaccord Genuity Group cut their price objective on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.00.

Heartflow Price Performance

Shares of Heartflow stock opened at $28.10 on Friday. The company has a 50-day moving average of $28.76 and a 200 day moving average of $28.27. The firm has a market cap of $2.42 billion and a price-to-earnings ratio of -9.04. Heartflow, Inc. has a 1 year low of $20.13 and a 1 year high of $41.22.

Heartflow (NASDAQ:HTFL) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The firm had revenue of $52.59 million for the quarter. Heartflow’s revenue for the quarter was up 41.3% compared to the same quarter last year. On average, equities analysts anticipate that Heartflow, Inc. will post -0.82 EPS for the current year.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.